Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin prediction
Frontiers in Oncology · 02.11.2026 · 16
DOI: 10.3389/fonc.2026.1984602 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 02.11.2026. Verfasst von Jinesh S Gheeya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The field of cancer-related liquid biopsy, largely defined as plasma circulating tumor DNA (ctDNA) analysis by next-generation sequencing (NGS), is rapidly evolving from genomics-only approaches to multiomic assays that add components such as DNA fragmentomics and epigenomics, with or without proteomics, to a genomic backbone. Here we describe how integration of epigenomic profiling, particularly tumor-specific methylation signatures, may extend ctDNA testing beyond detection of genomic alterations toward broader molecular phenotyping, with applications in alternative approaches to tumor fraction quantification, enhanced detection of actionable genomic biomarkers and mechanisms of resistance, histologic and lineage characterization, and cancer signal of origin prediction. This evolution has facilitated the clinical application of liquid biopsy across the cancer care continuum, from screening/early detection to determining minimal residual disease (MRD) in early-stage cancers to selecting treatment and determining mechanisms of acquired resistance in advanced-stage cancers. These new multiomic assays may also support prospective biomarker-driven clinical trials incorporating complementary measures of tumor burden, genomic alterations, and molecular phenotype. Collectively, these advances suggest that multiomic liquid biopsy platforms may represent a major advance in precision oncology, enabling dynamic and comprehensive characterization of tumor biology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
- Guardant Health, Inc., Palo Alto, CA, United States.
- Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States.
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Zitieren
APA
Gheeya, J. S., Welch, L., Porter, J., Gordon, S., Riess, J., Gadgeel, S., & Gandara, D. R. (2026). Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin prediction. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1984602
Vancouver
Gheeya JS, Welch L, Porter J, Gordon S, Riess J, Gadgeel S, et al. Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin prediction. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1984602
BibTeX
@article{Gheeya2026,
author = {Gheeya, Jinesh S and Welch, Lauren and Porter, Jason and Gordon, Sean and Riess, Jonathan and Gadgeel, Shirish and Gandara, David R},
title = {Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin prediction},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1984602}
}
EUVIMED